Showing results (151-160 of 160) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Journal of Translational Medicine|August 22, 2025
In silico prediction of optimal multifactorial intervention in chronic kidney diseaseAgnieszka Latosinska, Ioanna K Mina, Thi Minh Nghia Nguyen, et al.NEJM Evidence|October 28, 2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney DiseaseKatja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, et al.Diabetes, Obesity & Metabolism|July 29, 2025
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre studyElisabeth B Stougaard, Mads R Andersen, Jonatan I Bagger, et al.Journal of the American Society of Nephrology : JASN|January 16, 2015
Diagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesJoost P Schanstra, Petra Zürbig, Alaa Alkhalaf, et al.The Lancet. Diabetes & Endocrinology|March 6, 2020
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trialNete Tofte, Morten Lindhardt, Katarina Adamova, et al.Journal of Diabetes and Its Complications|February 25, 2023
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trialViktor Rotbain Curovic, Nete Tofte, Morten Lindhardt, et al.European Journal of Clinical Investigation|April 24, 2012
Implementation of proteomic biomarkers: making it workHarald Mischak, John P A Ioannidis, Angel Argiles, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 5, 2014
Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathyJustyna Siwy, Joost P Schanstra, Angel Argiles, et al.BMJ Open|February 26, 2026
Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysisLuxcia Kugathasan, Massimo Nardone, Marcel Muskiet, et al.Pageof 16